Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Chames

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 25, 2025
Nanobody-enhanced T cell cancer immunotherapy: Advancing precision medicineRemy Boisgard, Juliette Prothon, Celia Torrielli, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|September 12, 2008
Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapyRalph Willemsen, Patrick Chames, Erik Schooten, et al.
Molecular Biosystems|July 10, 2012
Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approachesKlervi Even-Desrumeaux, Patrick Fourquet, Véronique Secq, et al.
Human Immunology|January 1, 2003
Genetic engineering of T cell specificity for immunotherapy of cancerRalph A Willemsen, Reno Debets, Patrick Chames, et al.
ACS Nano|January 21, 2015
Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimersDamien Nevoltris, Benjamin Lombard, Elodie Dupuis, et al.
Biophysical Journal|April 14, 2019
Nanobody-CD16 Catch Bond Reveals NK Cell MechanosensitivityCristina González, Patrick Chames, Brigitte Kerfelec, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 24, 2026
Optimizing nanobody-based molecules targeting mesothelin: Exploring format, valency, size, and half-life for next-generation cancer theranosticsRemy Boisgard, Darcy MacFarland, Armelle Goubard, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine productionRalph A Willemsen, Cees Ronteltap, Patrick Chames, et al.
Nucleic Acids Research|November 25, 2005
In vivo selection of engineered homing endonucleases using double-strand break induced homologous recombinationPatrick Chames, Jean-Charles Epinat, Sophie Guillier, et al.
Journal of Biomedical Nanotechnology|August 27, 2015
Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical ApplicationsAndrew M Prantner, Marc Turini, Brigitte Kerfelec, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 25, 2025
Nanobody-enhanced T cell cancer immunotherapy: Advancing precision medicineRemy Boisgard, Juliette Prothon, Celia Torrielli, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|September 12, 2008
Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapyRalph Willemsen, Patrick Chames, Erik Schooten, et al.
Molecular Biosystems|July 10, 2012
Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approachesKlervi Even-Desrumeaux, Patrick Fourquet, Véronique Secq, et al.
Human Immunology|January 1, 2003
Genetic engineering of T cell specificity for immunotherapy of cancerRalph A Willemsen, Reno Debets, Patrick Chames, et al.
ACS Nano|January 21, 2015
Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimersDamien Nevoltris, Benjamin Lombard, Elodie Dupuis, et al.
Biophysical Journal|April 14, 2019
Nanobody-CD16 Catch Bond Reveals NK Cell MechanosensitivityCristina González, Patrick Chames, Brigitte Kerfelec, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 24, 2026
Optimizing nanobody-based molecules targeting mesothelin: Exploring format, valency, size, and half-life for next-generation cancer theranosticsRemy Boisgard, Darcy MacFarland, Armelle Goubard, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine productionRalph A Willemsen, Cees Ronteltap, Patrick Chames, et al.
Nucleic Acids Research|November 25, 2005
In vivo selection of engineered homing endonucleases using double-strand break induced homologous recombinationPatrick Chames, Jean-Charles Epinat, Sophie Guillier, et al.
Journal of Biomedical Nanotechnology|August 27, 2015
Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical ApplicationsAndrew M Prantner, Marc Turini, Brigitte Kerfelec, et al.
Pageof 9